Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Contributed by: GlobeNewswire

Tags

Healthcare

More Like This

Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP

Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP

Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025

Beacon Therapeutics Announces Positive Interim 9+ Month Results from DAWN Trial and 36-Month Phase 2 SKYLINE Trial Data for Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at EURETINA 2025

Beacon Therapeutics Announces EURETINA 2025 Presentations on 9+-Month Phase 2 DAWN and 36-Month Phase 2 SKYLINE Trial Data for laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)

Beacon Therapeutics Treats First Patient in LANDSCAPE Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)

Beacon Therapeutics Annouces Presentations at the ARVO 2026 Annual Meeting